Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K current report with the SEC on February 27, 2026 reporting Item 7.01 (Regulation FD Disclosure). OCUL presenting SOL-1 Phase 3 superiority trial results for AXPAXLI (OTX-TKI) in wet AMD at Macula Society Annual Meeting Feb 27.
OCULAR THERAPEUTIX, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- OCUL presenting SOL-1 Phase 3 superiority trial results for AXPAXLI (OTX-TKI) in wet AMD at Macula Society Annual Meeting Feb 27
- "Superiority" trial design is a high bar: positive results would signal AXPAXLI outperforms existing standard-of-care treatments
- Slides posted to investor website at 4:15pm ET Feb 27; wet AMD is a large commercial market, making trial outcome highly material to valuation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OCULAR THERAPEUTIX, INC 8-K filings
Get the next OCUL 8-K as it lands
Follow OCUL for push alerts, or ask the research agent what this filing means.